CPIX - Cumberland Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.01
+0.14 (+2.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.87
Open5.81
Bid5.75 x 800
Ask12.00 x 800
Day's Range5.80 - 6.03
52 Week Range5.53 - 7.96
Volume11,362
Avg. Volume16,561
Market Cap94.423M
Beta0.36
PE Ratio (TTM)N/A
EPS (TTM)-0.57
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.25
Trade prices are not sourced from all markets
  • What You Must Know About Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) Financial Strength
    Simply Wall St.10 days ago

    What You Must Know About Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) Financial Strength

    Investors are always looking for growth in small-cap stocks like Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), with a market cap of US$94.27M. However, an important fact which most ignore is: how financiallyRead More...

  • Thomson Reuters StreetEvents13 days ago

    Edited Transcript of CPIX earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Cumberland Pharmaceuticals Inc Earnings Call

  • Associated Presslast month

    Cumberland: 1Q Earnings Snapshot

    On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 15 cents. Losses, adjusted for one-time gains and costs, came to 9 cents per share. The pharmaceutical company posted ...

  • PR Newswirelast month

    Cumberland Pharmaceuticals Reports First Quarter 2018 Financial Results

    - Caldolor® sNDA accepted by the FDA - Advancing four Phase II clinical programs NASHVILLE, Tenn. , May 8, 2018 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical ...

  • PR Newswire2 months ago

    Cumberland Pharmaceuticals To Announce First Quarter 2018 Financial Results

    NASHVILLE, Tenn., May 1, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) announced today that it will release first quarter 2018 financial results after the market closes on Tuesday, May 8, 2018.  A conference call and live Internet webcast will be held on Tuesday, May 8, 2018, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers).  The Conference ID for the rebroadcast is 4296607. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

  • Cumberland Pharmaceuticals Expands into Oncology Support
    PR Newswire2 months ago

    Cumberland Pharmaceuticals Expands into Oncology Support

    NASHVILLE, Tenn., April 9, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals – announced today that it has expanded its medical specialties to include oncology-related medications. "Since the company's founding, Cumberland has endeavored to deliver high quality medicines to improve patient care," said CEO AJ Kazimi. As a result, quality of life becomes of paramount concern – and Cumberland's focus is on supporting cancer patients during their treatment, with the goal of improving their ongoing quality of life.

  • Why Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) Ownership Structure Is Important
    Simply Wall St.3 months ago

    Why Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) Ownership Structure Is Important

    Today, I will be analyzing Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure has been found to have an impact onRead More...

  • PR Newswire3 months ago

    Newly Published Data Demonstrates 85% Eradication of Ulcer Causing Bacteria

    NASHVILLE, Tenn., March 26, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a U.S. specialty pharmaceutical company announced today the publication of an open access article in Infection and Drug Resistance, with results demonstrating an 85% eradication rate of Helicobacter pylori (H. pylori) infection using clarithromycin-based triple therapy. Cumberland markets a branded clarithromycin-based triple therapy in the U.S. under the name Omeclamox®-Pak. H. pylori has long been known as a common pathogen associated with gastric ulcers and related dyspeptic symptoms in many infected patients.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CPIX earnings conference call or presentation 6-Mar-18 9:30pm GMT

    Q4 2017 Cumberland Pharmaceuticals Inc Earnings Call

  • Associated Press3 months ago

    Cumberland reports 4Q loss

    The Nashville, Tennessee-based company said it had a loss of 5 cents per share. Earnings, adjusted for one-time gains and costs, came to 3 cents per share. The pharmaceutical company posted revenue of ...

  • PR Newswire3 months ago

    Cumberland Pharmaceuticals Reports 25% Revenue Growth For The Full Year 2017

    - National sales and distribution of Totect® initiated - New Data on Caldolor® and Vaprisol® published - Co-promotion for Kristalose® launched NASHVILLE, Tenn. , March 6, 2018 /PRNewswire/ --  Cumberland ...

  • ACCESSWIRE3 months ago

    Cumberland Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018 at 4:30 PM Eastern ...

  • PR Newswire4 months ago

    Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2017 Financial Results

    NASHVILLE, Tenn. , Feb. 27, 2018 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2017 financial results after the market closes ...

  • Why You Need To Look At This Factor Before Buying Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)
    Simply Wall St.4 months ago

    Why You Need To Look At This Factor Before Buying Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)

    For Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...

  • Is Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) A Financially Sound Company?
    Simply Wall St.4 months ago

    Is Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) A Financially Sound Company?

    Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a small-cap stock with a market capitalization of US$109.29M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...

  • PR Newswire5 months ago

    Newly Published Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients

    Amifostine may prevent gastro-intestinal toxicities in certain cancer patients. NASHVILLE, Tenn. , Jan. 30, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a U.S. specialty pharmaceutical ...

  • American City Business Journals6 months ago

    The fastest-growing Nashville health care company of 2017 might surprise you

    Nashville is well known for the collection of health care providers that call Music City home. Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company founded in 1999, has seen its stock price rise more than 33 percent to $7.35, and as high as 44 percent, since the beginning of the year. Community Healthcare Trust Inc.’s stock price has risen second-fastest at almost 22 percent, as of today.

  • Is Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) Excessively Paying Its CEO?
    Simply Wall St.6 months ago

    Is Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) Excessively Paying Its CEO?

    A. Kazimi took the helm as Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) CEO and grew market cap to $116.38M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • Who Owns Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)?
    Simply Wall St.6 months ago

    Who Owns Cumberland Pharmaceuticals Inc (NASDAQ:CPIX)?

    In this article, I’m going to take a look at Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Cumberland Pharmaceuticals Inc (CPIX): How Much Growth Is Left In Healthcare?
    Simply Wall St.7 months ago

    Cumberland Pharmaceuticals Inc (CPIX): How Much Growth Is Left In Healthcare?

    Cumberland Pharmaceuticals Inc (NASDAQ:CPIX), a USD$125.35M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of CPIX earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 Cumberland Pharmaceuticals Inc Earnings Call

  • Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
    Capital Cube7 months ago

    Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Cumberland Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Cumberland Pharmaceuticals, Inc. – Ironwood Pharmaceuticals, Inc. Class A, Pernix Therapeutics Holdings, Inc., DURECT Corporation, Akorn, Inc., Merck & Co., Inc., Mylan N.V., Sucampo Pharmaceuticals, Inc. Class A ... Read more (Read more...)

  • Associated Press7 months ago

    Cumberland reports 3Q loss

    On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 5 cents. Earnings, adjusted for non-recurring costs and stock option expense, were 1 cent per share. The pharmaceutical ...

  • PR Newswire7 months ago

    Cumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter

    - Launched Totect® in the United States - Implemented Kristalose® Co-Promotion Agreement NASHVILLE, Tenn. , Nov. 7, 2017 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical ...